Spain· ES:50560
LANIRAPID 0,1 mg COMPRIMIDOS
A medicinal product containing metildigoxina, registered in Spain by Kern Pharma S.L..
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- metildigoxina
- Manufacturer
- Kern Pharma S.L.
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cima_codigo65342650EUR 4.57
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Metildigoxina in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Authorised across Europe · EMA
The same active substance is authorised in 7 EEA countries. Names it is sold under:
- Austria · Lanitop®
- Belgium · Lanitop
- Bulgaria · Ланитоп
- Germany · Lanitop
- Croatia · Lanitop
- Portugal · Lanitop
- Slovenia · Lanitop
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b16f1176-b0a2-492b-96fa-8f55c7d79b28 GET /v1/drugs/b16f1176-b0a2-492b-96fa-8f55c7d79b28?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración",
"estado": "{\"aut\":86742000000}",
"nregistro": "50560",
"substance": "metildigoxina"
}See everything about metildigoxina.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.